拉氧头孢治疗肺部感染的临床疗效及安全性分析

Clinical efficacy and safety of Chinese Journal of Integrative Medicine on Cardio/Cerebrovascular Disease

目的探析肺部感染患者用拉氧头孢进行治疗的病情控制效果、不良反应情况。方法重症肺部感染患者60例,来自2016年10月至2017年10月本院接受诊治群体,编序并随机数字表将其分为常规组、拉氧头孢组,对应治疗药物为头孢匹胺、拉氧头孢,各组患者30例。比较疗程后患者临床疗效和安全性。结果 (1)两组患者临床疗效对比:拉氧头孢组患者病情改善情况显著优于常规组(P<0.05);(2)两组患者安全性对比:拉氧头孢组患者药物安全性显著优于常规组(P<0.05);结论对肺部感染患者用头孢类抗菌药物治疗对病情有较好的干预作用,相对而言拉氧头孢临床应用价值更为突出,安全性高,保障患者疗程的顺利进行和生活质量,值得临床应用。

Objective Analysis of pulmonary infection patients with Cefradine treatment of disease control effect, adverse reactions. Methods 60 patients with severe pulmonary infection were enrolled in the study group from October 2016 to October 2017. The patients were divided into the conventional group and the random number table. The corresponding treatment drugs were cephalosporins Song song, pull oxygen cephalosporins, each group of patients in 30 cases. Comparison of clinical efficacy and safety of patients after treatment. Results(1) The clinical efficacy of the two groups : the improvement of the condition of the patients in the moxalactam group was significantly higher than that of the conventional group(P<0.05);(2) The safety of the two groups :moxalactam group the drug safety of the group was significantly better than that of the conventional group(P<0.05).Conclusion The treatment of cephalosporins in patients with pulmonary infection has a better intervention effect on the disease. In contrast, the clinical application value of leucophylla cephalosporins is more prominent, and the safety is high, the patient's course of treatment and quality of life, worthy of clinical application.